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A B S T R A C T
Voluntary termination of pregnancy (VTP), pre-conception and post-partum phases, as well as Occupational
Medicine consultation for healthcare workers are opportunities for screening and vaccinating rubella ser-
onegative childbearing women. However, data about vaccination acceptance following these phases is rarely
reported.
A retrospective study over a 2-year period (2016–2017) was performed, evaluating the prevalence of rubella
seronegative women which underwent VTP (wVTP), mothers in early puerperal phase (mEPP) and childbearing
healthcare workers (CbHW) aged 15–49 years. Anti-rubella vaccination rates and factors associated with vaccine
hesitancy (VH) were investigated.
Anti-rubella IgG titres were assessed in 8623 women. Seroprevalence of rubella susceptibility was 7.9%
(wVTP 6.4%; mEPP 17.4%; CbHW 9.3%). Anti-rubella vaccination rates were found to be different in the three
groups (wVTP 37.1%; mEPP 10.9%; CbHW 25.4%), specifically in 2016 and among women born in Italy. VH rate
was higher in 2017, especially among wVTP and CbHW. Anti-rubella vaccination rates in wVTP vs. mEPP was
higher in women born in Italy but not in those born abroad. Multivariable analyses demonstrated significantly
higher risk of VH for mEPP (OR 8.2; 95% CI: 3.9–16.9) and women reporting history of allergy to drugs, food or
environmental agents (OR 2.7; 95% CI: 1.4–5.1).
During the analyzed period childbearing women included in this study were not adequately protected against
rubella. Anti-rubella vaccination rates were widely unsatisfactory. Being mEPP and reporting allergy were
significantly associated to higher rates of VH. Tailored strategies targeting on vaccine safety are needed for
retention of these women in immunisation programmes.
1. Introduction
Rubella is a viral infection, which is spread through the respiratory
route. It is presently considered a re-emerging vaccine-preventable
disease together with measles and mumps. It mostly results in self-
limiting upper respiratory symptoms, fever, lymphadenopathy and
cranial/cervical-distal maculopapular rash. Among adults, complica-
tions such as encephalitis, haemorrhagic syndromes and orchitis have
been largely described. During pregnancy, rubella virus can infect both
placenta and foetus increasing morbidity, disability and mortality load
(Lambert et al., 2015). During the first trimester, rubella infection can
lead to miscarriage, death of foetus, stillbirth, or congenital rubella
syndrome. After week 31 of gestation vertical transmission risk in-
creases progressively, climbing up to 100% at week 36. Moreover, an
increased risk of endocrinopathies such as thyroiditis and diabetes
mellitus has been found to be associated with congenital rubella in-
fection (Schwarz, 2017).
Eliminating rubella in five World Health Organization regions in
order to prevent rubella infection complications is an international
community aim for 2020 (The Global Vaccine Action Plan 2015–2020,
2012; European Vaccine Action Plan 2015–2020, 2014). Providing free of
charge, measles, mumps and rubella (MMR) vaccines to all adolescents
and adults has been established to be the right strategy in order to re-
duce rubella susceptibility below 5%.
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Vaccine hesitancy (VH) has been defined as a delay in acceptance or
refusal of vaccine despite availability of vaccination services. Causes of
VH are multiple, various and context-related, usually linked to com-
placency, convenience and confidence (MacDonald, 2015). Low health
professional education about evidence of vaccination effectiveness,
benefits and safety and patient beliefs have been considered the main
obstacles to satisfactory vaccination coverage (Giambi et al., 2018;
Stark et al., 2016; La Torre et al., 2017; Little et al., 2015).
Voluntary termination of pregnancy (VTP), pre-conception and
post-partum phases (Hisano et al., 2016), as well as Occupational
Medicine assessments for healthcare workers were deemed to be op-
portunities for screening and vaccinating rubella seronegative women
of childbearing potential. However, data about vaccination acceptance
following these phases is rarely reported or considered suboptimal
(Little et al., 2015; Pettinicchio et al., 2018; Santoro et al., 2016). In
spite of implementation of several immunisation strategies, as in-hos-
pital vaccination before discharge or active calls by public health ser-
vices, anti-rubella vaccination rates following VTP in Italy have been
considered worrying and widely unsatisfactory (Pettinicchio et al.,
2018). Italian surveillance data from 2005 to 2013 reported 75 cases of
congenital rubella infection and 160 cases of rubella infection in
pregnancy, highlighting a probable underestimation due to unclassified
newborns and women lost to follow-up (Giambi et al., 2015). Identi-
fying rubella susceptibility and factors related to VH in childbearing
women is necessary to develop and implement tailored strategies
(Jarrett et al., 2015) which can prevent rubella infection complications,
above all during pregnancy.
The aims of this study were to assess rubella susceptibility and anti-
rubella vaccination rates of seronegative women which underwent VTP
(wVTP), mothers in early puerperal phase (mEPP) and childbearing
healthcare workers (CbHW). Where available, factors associated to VH
in wVTP and mEPP were also evaluated in order to help clinicians
identify women at higher risk of VH that should be included in targeted
strategies aiming at higher retention in vaccination programmes.
2. Materials and methods
A monocentric retrospective study over a 2-year period
(2016–2017) was performed at a tertiary hospital, primarily evaluating
prevalence of rubella susceptibility in wVTP, mEPP and CbHW aged
15–49 years. Demographic characteristics and first dose anti-rubella
vaccination rates before discharge for wVTP and mEPP and at the time
of Occupational Medicine consultation for CbHW were analyzed and
compared among groups. All the anti-rubella seronegative women
which refused anti-rubella vaccination were considered hesitant.
wVTP and mEPP were compared and factors related to VH assessed.
Age, country of birth (born in Italy vs. born abroad), parity (≥1 child
vs. nulliparous), previous VTP, reported comorbidities, allergy to drug/
food/environmental agents, week of gestation at the time of termina-
tion in wVTP and performance of caesarean delivery in mEPP were the
variables available in the medical records that have been analyzed in
these two groups only, as they were not available for CbHW. Patient
records were anonymized and de-identified prior to analysis. The study
was not submitted to the Ethics Committee's approval because it was
carried out within the local transposition of what the Italian National
Plan for the Elimination of Measles and Congenital Rubella advised.
Anti-rubella immunoglobulin G (IgG) titres were assessed using
chemiluminescent immunoassay technology (Liaison XL – DiaSorin,
Saluggia, Italy), according to the manufacturer's instructions. Serum
samples with anti-rubella IgG≥10 IU/ml were considered positive and
serum samples with anti-rubella IgG≤6 IU/ml were considered nega-
tive. Intermediate serologic results (6.1–9.9 IU/ml) were reassessed
with enzyme linked fluorescent assay (VIDAS – bioMérieux, Marcy
l'Étoile, France), which were then considered negative when second
appraisal of anti-rubella IgG titres were ≤10 IU/ml.
Descriptive data are shown as absolute (n) and relative (%)
frequencies for categorical data and as mean ± standard deviation
(SD) for continuous variables. At univariate analysis, Chi-square test
was carried out for categorical variables, and analysis of variance
(ANOVA) with Bonferroni correction for continuous variables in order
to assess whether significant differences could be detected among the 3
groups. Chi-square test or Fisher's exact test, as appropriate, were also
performed to compare wVTP and mEPP and to detect possible pre-
dictors of VH stratifying by year of serology testing.
Multivariable analysis models were then fitted to evaluate the in-
dependent effect of clinically relevant variables and those that turned
out to be significantly associated to VH at univariate analysis: VH was
set as the dependent variable of a logistic regression model whereas
group (wVTP vs. mEPP), age, country of birth (born in Italy vs. born
abroad), parity (≥1 child vs. nulliparous) and allergy were taken as
independent variables. For all tests, a p-value ≤0.05 was considered
significant. All analyses were performed with Stata 14.
3. Results
3.1. Seroprevalence of rubella susceptibility and anti-rubella vaccination
rates
Anti-rubella IgG titres were assessed in 8623 women (wVTP
n=6319; mEPP n=780; CbHW n=135). Most of them (66.7%;
n=5748) were born in Italy: 61% (n=3852), 60.4% (n=471) and
93.5% (n=1425) of wVTP, mEPP and CbHW, respectively. The overall
prevalence of rubella susceptibility was 7.9% (n=680): 6.4%
(n= 402), 17.4% (n= 136), 9.3% (n=142) in wVTP, mEPP and
CbHW, respectively. The prevalence of rubella susceptibility in women
born in Italy (8.5%; n= 490) was generally found to be higher than in
women born abroad (6.6%; n=190). Among women born in Italy the
prevalence of rubella susceptibility was 6.8% (n=262), 19.3%
(n= 91) and 9.6% (n= 137) in wVTP, mEPP and CbHW, respectively.
Showing a similar trend, prevalence of rubella susceptibility among
women born abroad was 5.7% (n= 140), 14.6% (n= 45), 5.1%
(n= 5) in wVTP, mEPP and CbHW, respectively.
Demographic characteristics and anti-rubella vaccination rates of
rubella seronegative women according to group are shown in Table 1.
Comparing the three groups, a statistically significant different dis-
tribution of age (p= 0.003) and country of birth (born in Italy vs. born
abroad; p < 0.001) were observed. mEPP were found to be older than
women of the other two groups; CbHW were almost all born in Italy.
Considering the whole sample of women born abroad, 31.2% were born
in Eastern Europe, 19.9% in Asia, 18.3% in Sub-Saharan Africa, 17.2%
in Central and South America, 11.8% in North African countries and
1.6% in Europe or North America (data not shown).
Data about anti-rubella vaccination rates of seronegative women
showed statistically significant differences among the three groups
(p < 0.001) with lower vaccination rate in mEPP. However, stratifying
by year and country of birth, this finding turned out to be significant
only in 2016 among women born in Italy (p < 0.001) but not in 2017,
neither among women born in Italy (p=0.054) nor among those born
abroad (p=0.436).
No significant differences were found for anti-rubella vaccination
rates when women born in Italy and those born abroad were compared
(p= 0.089), even after year stratification. VH turned out to be sig-
nificantly higher in 2017 than in 2016 (p < 0.001) among women of
both groups. Among women born abroad, no association between
macro-region of birth and VH was observed (p=0.882), both in 2016
and 2017 (data not shown).
3.2. Focus on wVTP and mEPP and factors related to vaccine hesitancy
Data and comparisons about anti-rubella vaccination rates and VH
in wVTP and mEPP groups, stratified by year, are shown in Table 2.
wVTP and mEPP were found to be similar for country of birth (born
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in Italy vs. born abroad; p=0.755 in 2016, p= 0.376 in 2017), parity
(p=0.178 in 2016; p=0.926 in 2017), allergy to drug/food/en-
vironmental agents (p=0.277 in 2016; p= 0.258 in 2017), but sig-
nificantly different for age (p=0.037 in 2016, p=0.010 in 2017),
previous VTP in 2016 (p= 0.027) and comorbidities (p < 0.001) both
in 2016 and 2017. Generally, wVTP were younger and had already
undergone VTP in the past more than mEPP while mEPP reported more
comorbidities.
About 23% of wVTP and 30% of women in mEPP group reported
history of allergy to either drugs, food or environmental agents.
Anti-rubella vaccination rate was found to be significantly higher in
wVTP than in mEPP in 2016 (p < 0.001), whereas no significant dif-
ferences were detected in 2017 (p=0.258). The same happened when
groups were compared stratifying for country of birth (born in Italy vs.
born abroad), as we found significant differences between the 2 groups
in 2016 among women born in Italy (p < 0.001), but not in 2017
(p=0.233). No differences were detected when the same comparisons
involved women born abroad.
mEPP and wVTP groups turned out to be significantly different
when compared for VH using 2016 data, also stratifying for parity
(nulliparous p < 0.001; ≥1 child p < 0.001), previous VTP
(p= 0.021) and history of allergy to drug/food/environmental agents
(p= 0.002). The same analyses on 2017 data did not detect significant
differences between the two groups.
Analyzing the two groups separately, no statistically significant as-
sociation was found between VH and week of gestation at time of VTP
in wVTP group (p=0.477) and between VH and caesarean delivery in
mEPP group (p=0.561), even when stratifying by year (data not
shown).
Likewise, no statistically significant associations, neither at uni-
variate nor at multivariable analysis, were found when 2017 data were
analyzed to detect possible predictors of VH. Table 3 shows the results
of univariate and multivariable analyses on 2016 data only. The sig-
nificant associations between VH and both mEPP and allergy history,
Table 1
Demographic characteristics and anti-rubella vaccination rates of rubella seronegative women according to group.
Total
n=680
Voluntary termination of
pregnancy
n= 402
Puerperal phase
n= 136
Childbearing healthcare
workers
n=142
p value
Mean age ± SD (years) 29.2 ± 7.7 28.5 ± 7.6 30.8 ± 6.2 28.5 ± 8.7 0.003
Born in Italy % (n) 72.1 (490) 65.2 (262) 66.9 (91) 96.5 (137) <0.001
Anti-rubella vaccination rate (n) % 30.4 (207) 37.1 (149) 16.2 (22) 25.4 (36) <0.001
Anti-rubella vaccination rate in 2016% (n) 47.9 (158) 60.6 (129) 16.7 (11) 35.3 (18) <0.001
Anti-rubella vaccination rate in 2017% (n) 14 (49) 10.6 (20) 15.7 (11) 19.8 (18) 0.104
Anti-rubella vaccination rate in patients born in Italy % (n) 28.6 (140) 36.6 (96) 9.9 (9) 25.6 (35) <0.001
Anti-rubella vaccination rate in 2016 in patients born in Italy
% (n)
46.5 (106) 61.4 (86) 4.8 (2) 36.7 (18) <0.001
Anti-rubella vaccination rate in 2017 in patients born in Italy
% (n)
13 (34) 8.1 (10) 14 (7) 19.3 (17) 0.054
Anti-rubella vaccination rate in patients born abroad % (n) 35.3 (67) 37.9 (53) 28.9 (13) 20 (1) 0.458
Anti-rubella vaccination rate in 2016 in patients born abroad
% (n)
51 (52) 58.9 (43) 37.5 (9) 0 (0) 0.052
Anti-rubella vaccination rate in 2017 in patients born abroad
% (n)
17.1 (15) 18.2 (10) 20 (4) 33.3 (1) 0.436
Bold values denote statistical significance at the p < 0.05 level.
Table 2
Data and comparisons about anti-rubella vaccination rates and vaccine hesitancy in wVTP and mEPP groups stratified by year.
2016 2017
Voluntary termination of
pregnancy
n= 213
Puerperal phase
n= 66
p value Voluntary termination of
pregnancy
n= 189
Puerperal phase
n= 70
p value
Mean age ± SD (years) 28.7 ± 7.8 30.9 ± 5.7 0.037 28.1 ± 7.4 30.8 ± 6.7 0.010
Born in Italy % (n) 65.7 (140) 63.6 (42) 0.755 65.6 (124) 71.4 (50) 0.376
Anti-rubella vaccination rate % (n) 60.6 (129) 16.7 (11) <0.001 10.6 (20) 15.7 (11) 0.258
Anti-rubella vaccination rate in patients born in
Italy % (n)
61.4 (86) 4.8 (2) <0.001 8.1 (10) 14 (7) 0.233
Anti-rubella vaccination rate % in patients born
abroad % (n)
58.9 (43) 37.5 (9) 0.064 18.2 (10) 20 (4) 0.428
Vaccine hesitancy % (n) 39.4 (84) 83.3 (55) <0.001 89.4 (169) 84.3 (59) 0.258
Nulliparous % (n)a 56.5 (108) 47 (31) 0.178 55.9 (100) 56.5 (39) 0.926
Vaccine hesitancy % (n) 40.7 (44) 87.1 (27) <0.001 88 (88) 82.1 (32) 0.359
≥1 child % (n)a 43.5 (83) 53 (35) 0.178 44.1 (79) 43.5 (30) 0.926
Vaccine hesitancy % (n) 37.4 (31) 80 (28) <0.001 89.9 (71) 86.7 (26) 0.633
Previous voluntary interruption of pregnancy % (n)a 32.5 (62) 18.2 (12) 0.027 20.7 (37) 11.6 (8) 0.097
Vaccine hesitancy % (n) 38.7 (24) 75 (9) 0.021 78.4 (29) 75 (6) 0.835
Comorbidity % (n)a 12.6 (24) 31.8 (21) <0.001 14 (25) 46.4 (32) <0.001
Vaccine hesitancy % (n) 50 (12) 66.7 (14) 0.259 80 (20) 87.5 (28) 0.441
Reported allergy to drug/food/environmental agents
% (n)a
23.6 (45) 30.3 (20) 0.277 23.5 (42) 30.4 (21) 0.258
Vaccine hesitancy % (n) 55.6 (25) 95 (19) 0.002 92.9 (39) 90.5 (19) 0.742
Bold values denote statistical significance at the p < 0.05 level.
a Data not available for: 22 women belonging to voluntary termination of pregnancy group in 2016; 10 and 1 woman belonging to voluntary termination of
pregnancy and puerperal phase groups respectively in 2017.
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which were found at univariate analysis were confirmed when the lo-
gistic regression model was carried out, showing a higher risk of VH
among mEPP (OR 8.2; 95% CI: 3.9–16.9) and for women reporting
allergy (OR 2.7; 95% CI: 1.4–5.1).
4. Discussion
The prevalence of rubella susceptibility was found to be higher than
5% over the analyzed period. Childbearing women included in this
study, especially if mEPP, turned out not to be adequately protected
against rubella. Our study also highlighted that women born in Italy
were more susceptible to rubella than women born abroad.
Furthermore, mEPP had a lower acceptance of anti-rubella vaccination
than women of the other two groups, especially in 2016 and if born in
Italy. Being mEPP and reporting allergy to drug/food/environmental
agents were shown as predictors of VH in 2016. This finding was ob-
served in the context of a reduction in anti-rubella vaccination rate
between 2016 and 2017, especially among wVTP and CbHW, and in
spite of a low anti-rubella vaccination rate in mEPP hampering an ac-
curate identification of factors related to VH. Being CbHW did not seem
to particularly improve attitude and behaviours toward vaccination.
The achieved prevalence of rubella susceptibility in this study
confirmed data of a recent meta-analysis (Pandolfi et al., 2017) showing
that, at a global level, the proportion of rubella-susceptible childbearing
women is still high. The higher susceptibility to rubella among women
born in Italy confirmed previous Italian reports focused on wVTP
(Pettinicchio et al., 2018) and continues to show a dramatically higher
susceptibility rates when compared to women born in other European
countries, especially if mEPP (Vilajeliu et al., 2015).
In this study, women born abroad seem to be well represented due
to their frequent access to hospital care for VTP and delivery proce-
dures, but our data showed differences to that extracted from the last
surveys on serological status among childbearing immigrants in Italy
(Fabiani et al., 2017; Lo Giudice et al., 2014; De Paschale et al., 2012).
We may speculate that it was probably due to their epidemiological
characteristics, possibly related to both origin from not-high migratory
pressure countries and sufficient length-of-stay in Italy contributing to
higher responsiveness to public health agenda targets.
Differences in anti-rubella vaccination rates especially in 2016 and
in women born in Italy were due to a higher VH in mEPP. This finding
was not confirmed in 2017 probably due to the increase in VH, espe-
cially among wVTP. No significant differences in anti-rubella vaccina-
tion rates were achieved in women born abroad along the study period
probably due to the same reason.
The higher rate of VH in 2017 than in 2016 both in women born in
Italy and abroad was probably the main finding of this study, but fur-
ther studies are needed to confirm this data and to follow possible
epidemiological and immunisation trends. Despite not being designed
to identify causes of VH, we may argue that one possible related cause
could be the divisive political electoral campaign, focusing on the re-
cently approved law on mandatory vaccinations in 2017 (Disposizioni
urgenti in materia di prevenzione vaccinale, n.d.), which increased
confusion on public perception about vaccines. Similarly, significant
anti-rubella vaccination rate differences between 2016 and 2017
prompted a separate analysis of factors related to VH after stratifying by
year. Despite MMR vaccine safety and its lack of untoward effects
(Finale et al., 2017), anti-rubella vaccination rate in mEPP, especially if
born in Italy, was lower than in the other groups, showing that VH-
related factors in the postpartum phase are probably context specific
and vaccination following delivery was probably considered more
stressful or harmful than after VTP. Moreover, we can also speculate
that a considerable percentage of mEPP, above all if multiparous and
with previous VTP, had already hesitated to be vaccinated in the past
and should be considered refractory. Reporting allergy to drug/food/
environmental agents as a factor associated with VH should work as a
flashing light alerting physicians at anamnesis for probable VH, but this
needs to be confirmed by other studies, maybe more specifically de-
signed to study this relationship. Low rates in anti-rubella vaccination
in CbHW showed that knowledge and confidence in recommended
immunisation practice are still far to be achieved (Genovese et al.,
2019).
The study has some limitations. Despite of being the first study as-
sessing and comparing rubella susceptibility and vaccination rates in
wVTP, mEPP and CbHW, childbearing women not screened for rubella
in our laboratory and vaccinated in our hospital centre were not in-
cluded in this study. This could have caused an underestimation of anti-
rubella immunisation rate. Another limitation includes having con-
sidered only the first dose of anti-rubella vaccination rates, blanking
adherence to the second one and vaccination possibly administered in
other health facilities.
5. Conclusions
This study shows that an important percentage of childbearing
women accessing a tertiary hospital care of one of the most populated
Italian cities are still susceptible to rubella infection, and that, most of
them, above all mEPP and those reporting allergy, hesitate to vaccinate.
Clinicians should be aware of these findings in order to develop dia-
logue-based strategies targeting vaccine safety for retention of these
women in immunisation programmes. Further qualitative and quanti-
tative studies are needed in order to confirm the achieved data and help
overcome sociocultural beliefs related to VH not examined in this
survey.
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Table 3
Uni- and multivariable analyses for vaccine hesitancy predictors. Data are shown as percentages (absolute frequencies) if not otherwise stated.
VH yes
n= 139
VH no
n=140
Univariate analysis Multivariable analysis
OR (CI 95%) p-Value OR (CI 95%) p-Value
mEPP (vs. wVTP group) 39.6 (55) 7.9 (11) 7.68 (3.59–16.4) <0.001 8.18 (3.95–16.9) <0.001
Born in Italy (vs. born abroad) 65.5 (91) 62.9 (88) 1.12 (0.68–1.83) 0.649 1.05 (0.58–1.89) 0.879
Parity, ≥1 child (vs. nulliparous) 45.4 (59) 46.5 (59) 0.96 (0.58–1.57) 0.863 0.91 (0.49–1.68) 0.765
Comorbidity, yes (vs. no) 20.0 (26) 15.0 (19) 1.42 (0.74–2.73) 0.288 – –
Reported allergy, yes (vs. no) 33.8 (44) 16.5 (21) 2.58 (1.41–4.73) 0.001 2.68 (1.40–5.15) 0.003
Mean age ± SD 28.9 ± 7.4 29.3 ± 7.3 – 0.586 0.98 (0.94–1.02) 0.438
Bold values denote statistical significance at the p < 0.05 level.
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